Fibroblast growth factor 2 gene therapy (ID Pharma)

成纤维细胞生长因子2基因疗法（ID Pharma）

Report date: 2025/09/29 20:01:14

Base Information

Drug NameFibroblast growth factor 2 gene therapy (ID Pharma)
Drug Alias NameRecombinant SeV-hFGF2/dF成纤维细胞生长因子2基因治疗 - ID PharmaSeV-hFGF2/dF重组SeV-hFGF2/dFSEV-10101 +[8] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > SeV vector
Mechanisms of ActionAngiogenesis inducersFGF2 gene transference
TargetsFibroblast growth factor 2
Therapy Area/IndicationsIschemiaIntermittent ClaudicationPeripheral Arterial Disease +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland ChinaJapan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPending
Originator CompaniesDnavec
China Registration ClassN/A

Develop Information

Active CompaniesKyushu University
Inactive CompaniesVgtc Gene Technology Company LtdShenzhen Salubris Pharmaceuticals Co Ltd
Active IndicationsIntermittent ClaudicationPeripheral Arterial Disease
Inactive IndicationsIschemiaArterial Occlusive DiseasesPeripheral arterial occlusive disorders

Other Information

ATC CodeN/A
Related LinksN/A